140 related articles for article (PubMed ID: 23061634)
1. Complete remission of multiple myeloma associated scleredema after bortezomib-based treatment.
Szturz P; Adam Z; Vašků V; Feit J; Krejčí M; Pour L; Hájek R; Mayer J
Leuk Lymphoma; 2013 Jun; 54(6):1324-6. PubMed ID: 23061634
[No Abstract] [Full Text] [Related]
2. Induction treatment of light chain deposition disease with bortezomib: rapid hematological response with persistence of renal involvement.
Minarik J; Scudla V; Tichy T; Pika T; Bacovsky J; Lochman P; Zadrazil J
Leuk Lymphoma; 2012 Feb; 53(2):330-1. PubMed ID: 21883030
[No Abstract] [Full Text] [Related]
3. Successful bone reconstruction after bortezomib therapy in a myeloma patient.
Tanaka T; Yamasaki R; Omura H; Hino N
Int J Hematol; 2011 Sep; 94(3):221. PubMed ID: 21861100
[No Abstract] [Full Text] [Related]
4. Successful treatment of multicentric Castleman's disease accompanying myeloma with bortezomib.
Khan AA; Siraj F; Bhargava M; Aggarwal S
BMJ Case Rep; 2012 Dec; 2012():. PubMed ID: 23264156
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib-induced acute pancreatitis in a patient with multiple myeloma.
Wang HH; Tsui J; Wang XY; Liu SS; Li J
Leuk Lymphoma; 2014 Jun; 55(6):1404-5. PubMed ID: 23927397
[No Abstract] [Full Text] [Related]
6. Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report.
Yuan ZG; Dun XY; Li YH; Hou J
J Hematol Oncol; 2009 Apr; 2():19. PubMed ID: 19400935
[TBL] [Abstract][Full Text] [Related]
7. [Multiple myeloma and intravenous immunoglobulins].
Feugier P; Tomowiak C; Daguindau N; Perrot A
Rev Med Interne; 2007 Jun; 28 Spec No 2():5-6. PubMed ID: 17893960
[No Abstract] [Full Text] [Related]
8. Interstitial pneumonitis caused by Pneumocystis jirovecii pneumonia (PCP) during bortezomib treatment.
Wondergem MJ; Grünberg K; Wittgen BP; Sonneveld P; Zweegman S
Histopathology; 2009 Apr; 54(5):631-3. PubMed ID: 19302537
[No Abstract] [Full Text] [Related]
9. Bortezomib-based therapy as induction regimen of an autograft program in front-line treatment of multiple myeloma with end-stage renal disease.
Siniscalchi A; Dentamaro T; Perrotti A; Tatangelo P; de Fabritiis P; Caravita T
Ann Hematol; 2010 Aug; 89(8):821-2. PubMed ID: 19953253
[No Abstract] [Full Text] [Related]
10. Efficacy of bortezomib in systemic extramedullary localizations of multiple myeloma.
Federico V; Breccia M; Petrucci MT; Loglisci G; Mansueto G; Mercanti C; Levi A; Cartoni C; Musto P; Alimena G
Clin Adv Hematol Oncol; 2012 Apr; 10(4):266-8. PubMed ID: 22706491
[No Abstract] [Full Text] [Related]
11. Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland.
Hrusovsky I; Emmerich B; von Rohr A; Voegeli J; Taverna C; Olie RA; Pliskat H; Frohn C; Hess G
Oncology; 2010; 79(3-4):247-54. PubMed ID: 21372599
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis and the current trends in multiple myeloma therapy.
Dmoszyńska A
Pol Arch Med Wewn; 2008 Oct; 118(10):563-6. PubMed ID: 19112817
[TBL] [Abstract][Full Text] [Related]
13. Drug pricing: No cure, no cost.
Jack A
BMJ; 2007 Jul; 335(7611):122-3. PubMed ID: 17641343
[TBL] [Abstract][Full Text] [Related]
14. Effects of bortezomib on bone disease in multiple myeloma.
Drake MT; Rajkumar SV
Am J Hematol; 2009 Jan; 84(1):1-2. PubMed ID: 19030185
[No Abstract] [Full Text] [Related]
15. A striking response to bortezomib in a patient with pleural localization of multiple myeloma.
Mangiacavalli S; Varettoni M; Zappasodi P; Pica G; Lazzarino M; Corso A
Leuk Res; 2009 Apr; 33(4):577-8. PubMed ID: 18842298
[No Abstract] [Full Text] [Related]
16. Bortezomib just for induction or also for maintenance in myeloma patients with renal impairment?
San Miguel JF
Haematologica; 2014 Jan; 99(1):5-6. PubMed ID: 24425688
[No Abstract] [Full Text] [Related]
17. Experiences with bortezomib in multiple myeloma - from Phase II studies to daily practice.
Schmitt S; Bertsch U; Goldschmidt H
Int J Clin Pharmacol Ther; 2010 Jul; 48(7):494-6. PubMed ID: 20557858
[No Abstract] [Full Text] [Related]
18. Extramedullary involvement: an emerging problem in multiple myeloma.
Molica S
Clin Adv Hematol Oncol; 2012 Apr; 10(4):268-9. PubMed ID: 22706492
[No Abstract] [Full Text] [Related]
19. Renal improvement in myeloma with bortezomib plus plasma exchange.
Burnette BL; Leung N; Rajkumar SV
N Engl J Med; 2011 Jun; 364(24):2365-6. PubMed ID: 21675906
[No Abstract] [Full Text] [Related]
20. Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.
Zannetti BA; Zamagni E; Santostefano M; De Sanctis LB; Tacchetti P; Mancini E; Pantani L; Brioli A; Rizzo R; Mancuso K; Rocchi S; Pezzi A; Borsi E; Terragna C; Marzocchi G; Santoro A; Cavo M
Am J Hematol; 2015 Jul; 90(7):647-52. PubMed ID: 25858483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
